Ontology highlight
ABSTRACT:
SUBMITTER: McLellan JS
PROVIDER: S-EPMC3050594 | biostudies-literature | 2010 Feb
REPOSITORIES: biostudies-literature
Nature structural & molecular biology 20100124 2
Motavizumab is approximately tenfold more potent than its predecessor, palivizumab (Synagis), the FDA-approved monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection. The structure of motavizumab in complex with a 24-residue peptide corresponding to its epitope on the RSV fusion (F) glycoprotein reveals the structural basis for this greater potency. Modeling suggests that motavizumab recognizes a different quaternary configuration of the F glycoprotein than that observed ...[more]